NASDAQ$OFIX

Orthofix Medical Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Reported net sales of $112 million with adjusted EPS of $0.10.

Orthofix Medical Inc. reported a 1.3% increase in net sales to $112 million for the quarter ended September 30, 2021. The company's EPS was $(0.11), and adjusted EPS was $0.10.

  • Net sales increased by 1.3% over the prior year period, reaching $112 million.
  • Global Spinal Implants and Orthopedics businesses experienced double-digit growth.
  • Over 60,000 M6-C artificial cervical discs have been implanted worldwide.
  • AccelStim PMA application was submitted for healing fresh fractures.

Headline financials

Total Revenue

$112M

Previous: $111M+1.3%
EPS (adj)

$0.10

Previous: $0.31-67.7%
Capital Expenditures

-$11.6M

Previous: -$11.6M+0.6%
Free Cash Flow

-$13.7M

Previous: -$6.97M-97.0%
Net Income

-$2.17M

Previous: $4.65M-146.6%
Operating Income

-$313K

Previous: $4.18M-107.5%
Gross Profit

$84.1M

Previous: $84.7M-0.7%
Cash & Equivalents

$82.7M

Previous: $79.8M+3.6%
Total Assets

$500M

Previous: $517M-3.2%
Stock-Based Comp

$3.84M

Previous: $3.84M+0.0%

Revenue & EPS history

Orthofix · Revenue · Quarterly

$112M

Q3 2021+1.3%vs Q3 2020
Beat estimate in 8 of 16 quarters(50%)
ActualEstimate

Revenue by segment

Orthofix · $99.6M total across 3 segments · Q3 2021

  • Bone Growth Therapies
    $45.2M-4.0%
  • Spinal Implants & Biologics
    $28.2M+10.4%
  • Global Limb Reconstruction
    $26.3M

Forward guidance

The Company expects net sales between $460.0 and $464.0 million for the year ended December 31, 2021.

Tailwinds

  • Continued strength of the M6-C disc.
  • Growth of the FITBONE system.
  • Recently bolstered 3D-printed titanium spinal interbody portfolio.
  • Diversification of biologics portfolio with products like Opus Mg Set.
  • Planned expansion of bone growth therapy portfolio with AccelStim.

Headwinds

  • Ongoing challenges of COVID on operations and financial results.
  • Potential delays or cancellations of surgeries due to hospital limitations.
  • Possible workforce disruptions due to illness, quarantines, or government actions.
  • Potential disruptions to the supply chain.
  • General economic weakness affecting customer spending.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-0.9%

Avg return

Earnings day

-2.6%

Avg return

5 days after

-3.4%

Avg return

30 days after

48%

31 / 65 earnings

Positive

+20.3%

Q2 2014

Best reaction

-18.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.8%-2.8%-13.8%
Q4 2025-7.0%-0.4%-13.2%
Q3 2025-7.4%-6.8%-1.0%
Q1 2025-10.8%-10.6%-20.9%
Q4 2024-3.5%-4.2%-11.0%
Q3 2024+5.5%+4.6%+1.2%
Q2 2024+13.8%+10.8%+16.7%
Q1 2024+10.7%+8.8%+0.6%
Q4 2023+8.1%+7.1%+8.6%
Q3 2023-12.5%-20.2%-3.2%
Q2 2023+9.9%+7.6%+1.3%
Q1 2023+1.0%-2.3%+6.7%
Q4 2022-7.7%-13.2%-15.5%
Q3 2022-2.2%+4.1%+30.5%
Q2 2022-6.6%-8.8%-20.9%
Q1 2022-10.5%-14.3%-11.6%
Q4 2021+4.0%+3.5%+0.4%
Q3 2021-5.9%-10.9%-18.6%
Q2 2021+8.9%+4.1%+12.4%
Q1 2021+0.5%-2.0%-8.7%
Q4 2020+0.6%-0.5%-7.3%
Q3 2020+5.2%+13.6%+10.8%
Q2 2020+4.5%+4.6%-13.4%
Q1 2020-1.9%-6.9%+3.9%
Q4 2019-18.5%-21.5%-40.9%
Q3 2019-16.8%-17.0%-9.6%
Q2 2019+0.1%+2.6%-5.5%
Q1 2019-2.6%-0.3%-10.9%
Q4 2018-8.5%-10.0%-14.8%
Q3 2018+7.4%+8.8%+4.1%
Q2 2018-15.1%-11.9%-12.1%
Q1 2018-13.4%-14.6%-10.5%
Q4 2017+6.4%+4.6%+8.4%
Q3 2017+8.8%+5.1%+9.6%
Q2 2017+9.9%+6.8%+12.3%
Q1 2017+1.4%+3.8%+8.2%
Q4 2016-6.1%-4.8%+2.6%
Q3 2016-3.8%-6.8%-1.5%
Q2 2016-10.4%-10.5%-4.8%
Q1 2016+0.4%
Q4 2015+2.8%
Q3 2015+14.4%
Q2 2015+13.8%
Q1 2015+0.4%
Q4 2014-10.8%
Q3 2014+20.3%
Q2 2014+20.3%
Q1 2014+4.2%
Q4 2013+14.1%
Q3 2013+1.1%
Q2 2013-0.8%
Q1 2013-16.4%
Q4 2012-4.9%
Q3 2012-2.8%
Q2 2012+4.5%
Q1 2011-0.7%
Q1 2012+1.0%
Q1 2010-4.8%
Q4 2011-4.8%
Q4 2009-4.8%
Q3 2010-7.4%
Q3 2011-7.4%
Q4 2010-9.5%
Q2 2010-9.5%
Q2 2011-9.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro